PathWhiz

PathWhiz ID	Pathway	Meta Data
PW144998 View Pathway	drug action Rimexolone Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 14:53 Last Updated: October 07, 2023 at 14:53
PW132449 View Pathway	metabolic Rimonabant Drug Metabolism Homo sapiens Rimonabant is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Rimonabant passes through the liver and is then excreted from the body mainly through the kidney. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: September 21, 2023 at 21:50 Last Updated: September 21, 2023 at 21:50
PW145667 View Pathway	drug action Rimonabant Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 16:20 Last Updated: October 07, 2023 at 16:20
PW145893 View Pathway	drug action Riociguat Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 16:55 Last Updated: October 07, 2023 at 16:55
PW128527 View Pathway	drug action Ripretinib Action Pathway Homo sapiens Ripretinib is a kinase inhibitor primarily used to treat advanced gastrointestinal stromal tumor (GIST) that has not responded well to other kinase inhibitors like sunitinib and imatinib. Marketed under the name Qinlock, this medication is manufactured by Deciphera Pharmaceuticals and received FDA approval on May 15, 2020. It is notable for being the first drug approved as a fourth-line therapy, specifically for patients who have previously undergone treatment with at least three other kinase inhibitors, including imatinib. Ripretinib's mechanism of action involves inhibiting protein kinases, including both wild type and mutant forms of platelet-derived growth factor receptor A (PDGFRA) and KIT, which are implicated in the majority of gastrointestinal stromal tumors (GIST). This medication has been shown to inhibit other genes like PDGFRB, BRAF, VEGF, and TIE2 in laboratory studies. Its unique dual mechanism involves binding to the kinase switch pocket as well as the activation loop, effectively turning off the kinase and halting its ability to promote uncontrolled cell growth. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Dorsa Yahya Rayat Created On: September 01, 2023 at 13:26 Last Updated: September 01, 2023 at 13:26
PW146893 View Pathway	drug action Ripretinib Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 19:18 Last Updated: October 07, 2023 at 19:18
PW176402 View Pathway	metabolic Ripretinib Predicted Metabolism Pathway Homo sapiens Metabolites of Ripretinib are predicted with biotransformer. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Omolola Created On: December 07, 2023 at 16:51 Last Updated: December 07, 2023 at 16:51
PW146910 View Pathway	drug action Risdiplam Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 19:20 Last Updated: October 07, 2023 at 19:20
PW124383 View Pathway	drug action Risedronate Homo sapiens Risedronic acid is indicated for the treatment of osteoperosis in men, treatment of Paget's disease, treatment and prevention of osteoperosis in postmenopausal women, and treatment and prevention of glucocorticoid-induced osteoperosisLabel. Risedronatic acid binds to bone hydroxyapatiteLabel. Bone resorption causes local acidification, releasing risedronic acid which is that taken into osteoclasts by fluid-phase endocytosis1. Endocytic vesicles are acidified, releasing risedronic acid to the cytosol of osteoclasts where they induce apoptosis through inhbition of farnesyl pyrophosphate synthase1. Inhibition of osteoclasts results in decreased bone resorption1. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Dorsa Yahya Rayat Created On: December 03, 2020 at 21:14 Last Updated: December 03, 2020 at 21:14
PW000272 View Pathway	drug action Risedronate Action Pathway Homo sapiens Risedronate (also named Actonel, Atelvia or Benet.) is a type of medication that used to treat numbers of bone diseases because of its affinity for hydroxyapatite. Risedronate targets farnesyl pyrophosphate (FPP) synthase by inhibiting the function of this enzyme in the mevalonate pathway, which prevent the biosynthesis of Geranyl-PP and farnesyl pyrophosphate. Geranyl-PP and farnesyl pyrophosphate are important for geranylgeranylation and farnesylation of GTPase signalling proteins. Lack of Geranyl-PP and farnesyl pyrophosphate will result in decreased rate of bond resorption and turnover as well as block the osteoclast activity, which lead to an increasing mass gain in bone (i.e. net gain in bone mass). BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: WishartLab Created On: August 22, 2013 at 10:45 Last Updated: August 22, 2013 at 10:45